Clinical Trials
50 trialsREAL-LU
Novartis
TNE-bien-DIF
Assistance Publique - Hôpitaux de Paris
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
GAPET-NET
University Hospital, Brest
GEP-NENs
Tongji Hospital
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
First Affiliated Hospital, Sun Yat-Sen University
TEGRELE
Central Hospital, Nancy, France
NEMESIs
University Hospital, Basel, Switzerland
AIM-NETs
Asan Medical Center
ECHO-NET
Istituto Clinico Humanitas
ROOT
Taproot Health
PREF-NET
Ipsen
RELAX
TerSera Therapeutics LLC
BANN
University Medical Center Groningen
VIDEO-NET
University Medical Center Groningen
5-HIAA
University Medical Center Groningen
HET-NET
University Medical Center Groningen
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
University Medical Center Groningen
JPETClinic
Jagiellonian University
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors
Sun Yat-sen University
ReSiPaTNE
University Hospital, Strasbourg, France
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
SELFIE
King's College London
NutriGIT
University Medicine Greifswald
A Real-world Comparison of FNB and FNA in IHC-required Lesions.
Huazhong University of Science and Technology
Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan
National Health Research Institutes, Taiwan
HRQoL During PRRT in Patients With NETs
Uppsala University
NET-SEQ
University Health Network, Toronto
RESiN
Vanderbilt-Ingram Cancer Center
PET/Ga68
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis
IRCCS Azienda Ospedaliero-Universitaria di Bologna
TNE-P-Ki
Institut Paoli-Calmettes
18F-AmBF3-TATE PET/CT for Imaging NET Patients
British Columbia Cancer Agency
SYMNET
Ipsen
OPERA
Ipsen
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Ipsen
The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET
Vastra Gotaland Region
NETMRI
CHU de Reims
PanTEN
University Hospital, Montpellier
SOPRANo
Ipsen
Non Interventional Post Marketing Programme in Neuroendocrine Tumours
Ipsen
RECOSY
Ipsen
NetNutr
Federico II University
GALTEP
University Hospital, Bordeaux
BESTTHERAPYNET
Zentralklinik Bad Berka
B-Receptor Signaling in Cardiomyopathy
Stanford University
NETPET
University Medical Center Groningen
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
University of Aarhus